Windtree Therapeutics Files 8-K

Ticker: WINTW · Form: 8-K · Filed: Aug 8, 2025 · CIK: 946486

Windtree Therapeutics Inc /De/ 8-K Filing Summary
FieldDetail
CompanyWindtree Therapeutics Inc /De/ (WINTW)
Form Type8-K
Filed DateAug 8, 2025
Risk Levellow
Pages1
Reading Time2 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

Topics: corporate-update, sec-filing

TL;DR

Windtree Therapeutics updated its address and contact info in an 8-K filing on Aug 4, 2025.

AI Summary

On August 4, 2025, Windtree Therapeutics, Inc. filed an 8-K report. The filing indicates that the company is located at 2600 Kelly Road, Suite 100, Warrington, Pennsylvania, 18976, and its principal executive offices are also at this address. The company's telephone number is 215-488-9300.

Why It Matters

This 8-K filing provides updated corporate information and addresses for Windtree Therapeutics, Inc., which is important for investors and stakeholders to have the most current contact and location details.

Risk Assessment

Risk Level: low — This filing is a routine corporate update and does not contain information that suggests a significant change in the company's risk profile.

Key Players & Entities

  • Windtree Therapeutics, Inc. (company) — Registrant
  • 2600 Kelly Road, Suite 100, Warrington, Pennsylvania, 18976 (location) — Principal executive offices address
  • 215-488-9300 (phone_number) — Registrant's telephone number
  • August 4, 2025 (date) — Date of earliest event reported

FAQ

What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to report current information as required by the Securities and Exchange Commission, specifically detailing the company's address and contact information.

What is the official address of Windtree Therapeutics, Inc.'s principal executive offices?

The official address of Windtree Therapeutics, Inc.'s principal executive offices is 2600 Kelly Road, Suite 100, Warrington, Pennsylvania, 18976.

When was the earliest event reported in this filing?

The earliest event reported in this filing occurred on August 4, 2025.

What is the telephone number for Windtree Therapeutics, Inc.?

The telephone number for Windtree Therapeutics, Inc. is 215-488-9300.

In which state was Windtree Therapeutics, Inc. incorporated?

Windtree Therapeutics, Inc. was incorporated in Delaware.

Filing Stats: 447 words · 2 min read · ~1 pages · Grade level 12.2 · Accepted 2025-08-08 16:54:53

Key Financial Figures

  • $0.001 — h registered Common Stock , par value $0.001 per share WINT The Nasdaq Capital Ma

Filing Documents

01

Item 8.01 Other Events Windtree Therapeutics, Inc. (the "Company") has terminated its 04-CL-2201 (SEISMiC-C) clinical study, A Multcenter, Randomized, Placebo- Controlled, Parallel Group Trial on the Safety and Efficacy of Istaxime for Cardiogenic SCAI Stage C (SEISMiC-C) (the "Study"), at 20 enrollments. The Company's decision to terminate the Study is related to the Company's limited resources and its desire to advance the development of istaroxime into the broader acute hear failure space, and was not a result of any safety concerns with the Study.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Windtree Therapeutics, Inc. By: /s/ Jed Latkin Name: Jed Latkin Title: President and Chief Executive Officer Date: August 8, 2025

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.